| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036242 |
| Receipt No. | R000041281 |
| Scientific Title | A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level : Randomised double-blind placebo-controlled trial |
| Date of disclosure of the study information | 2019/03/18 |
| Last modified on | 2020/03/05 (Ver. 2) |
| Basic information | ||
| Public title | A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level : Randomised double-blind placebo-controlled trial | |
| Acronym | A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level | |
| Scientific Title | A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level : Randomised double-blind placebo-controlled trial | |
| Scientific Title:Acronym | A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of test food intake on the suppression of the elevation of postprandial blood glucose after ingesting glucose. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Blood glucose
*Measure at before ingestion and 30, 60, 90, and 120 minutes after ingestion. |
| Key secondary outcomes | Insulin
*Measure at before ingestion and 30, 60, 90, and 120 minutes after ingestion. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Food containing test food + glucose 75 g, single ingestion [Wash out for 1 week] Food not containing test food + glucose 75 g, single ingestion | |
| Interventions/Control_2 | Food not containing test food + glucose 75 g, single ingestion [Wash out for 1 week] Food containing test food + glucose 75 g, single ingestion | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Males and females, aged 20 - 65 years old.
2) Subjects whose fasting blood glucose level is from 110 mg/dL to 125 mg/dL or two-hour blood glucose level after 75 g glucose loading is from 140 mg/dL to 199 mg/dL, and who are judged normal-high or borderline type as the state of glycemia by the principal investigator. 3) Subjects who can make self-judgment and are voluntarily giving written informed consent. |
|||
| Key exclusion criteria | 1) Subjects whose fasting blood glucose level is greater than or equal to 126 mg/dL and two-hour blood glucose level after 75 g glucose loading is greater than or equal to 200 mg/dL.
2) A medical history of malignant tumor, heart failure or myocardial infarction. 3) Currently undergoing treatment for any of the following chronic diseases: atrial fibrillation, cardiac arrhythmia, liver failure, kidney failure, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4) Subjects who currently taking medications (including herbal medicines) 5) Subjects who are allergic to medications and/or the test food related products. 6) Subjects with irregular life rhythms such as shift workers, irregular eating habits. 7) Subjects who are pregnant, breast-feeding, or planning to get pregnant. 8) Subjects who have been enrolled in other clinical trials within the last 4 weeks before the agreement to participate in this trial. 9) Subjects who are considered as ineligible to participate in the study by the physician. |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Allegro Inc. | ||||||
| Division name | Clinical trial promotion department | ||||||
| Zip code | 151-0051 | ||||||
| Address | 4F, BML Bldg. 5-21-3, Sendagaya, Shibuya-ku, Tokyo | ||||||
| TEL | 03-5363-6821 | ||||||
| y-maki@bml.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Allegro Inc. | ||||||
| Division name | Clinical trial promotion department | ||||||
| Zip code | 151-0051 | ||||||
| Address | 4F, BML Bldg. 5-21-3, Sendagaya, Shibuya-ku, Tokyo | ||||||
| TEL | 03-5363-6821 | ||||||
| Homepage URL | |||||||
| f-kase@bml.co.jp | |||||||
| Sponsor | |
| Institute | Allegro Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Pharma Foods International Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | MC Food Specialties Inc. |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Tomisaka Clinic |
| Address | 1-33-9, Hongo, Bunkyo-ku, Tokyo |
| Tel | 03-3814-2662 |
| info@tomisaka.or.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041281 |